



16 July 2025

ASX Announcement

SHAREHOLDER TOWN HALL WEBINAR – 12PM AEST ON WEDNESDAY, 23 JULY 2025

InhaleRx Ltd (ASX: IRX), (“**InhaleRx**”, “**IRX**” ‘or “the **Company**”) a clinical-stage drug development company specialising in inhaled therapies to address unmet medical needs in pain management and mental health sectors, is pleased to invite shareholders to a webinar on Wednesday, 23 July 2025, commencing at 12pm AEST.

The webinar will provide an update on the Company’s activities over the past quarter, focusing on progress with the Company’s clinical development programs for IRX-211 and IRX-616a.

To access the webinar, please use the following link:

<https://us02web.zoom.us/j/89026377773?pwd=1LJ7heCtnkyd6l8wZo73V0MskkfY85.1>

Shareholders are encouraged to email any specific questions they would like addressed by 5pm AEST on Tuesday, 22 July 2025 to: info@inhalerx.com.au

Those shareholders who are unable to attend are similarly encouraged to email their questions by the above closing date and time.

A copy of the presentation slides for the webinar will be lodged on the ASX immediately prior to the webinar commencing.

This announcement has been authorised for release by the Board of InhaleRx Limited.

For further information:

www.inhalerx.com.au

info@inhalerx.com.au

James Barrie, Company Secretary

Phone +61 3 8678 4091

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian clinical stage drug development company which is developing rapid onset, inhaled therapies to address unmet medical needs in the pain management and mental health sectors. The Company has secured a funding facility of up to \$38.5m to accelerate the development of IRX-211 to treat Breakthrough Cancer Pain (“**BTcP**”), and IRX-616a to treat Panic Disorder.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for InhaleRx and the Company’s shareholders, as the clinical indications under investigation have been carefully selected in consultation with regulatory authorities. Bringing new approved medications to market will address critical gaps where there’s currently mismatched treatment options that can carry dependency concerns.

